Name: Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of serine hydrolases in mouse brain membrane in vitro set 3. ..more
BioActive Compounds: 12
Depositor Specified Assays
Show more |
| AID | Name | Type | Probe | Comment |
|---|---|---|---|---|
| 504411 | Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB) | screening | Primary screen (DAGLB inhibitors in singlicate) | |
| 504420 | Summary of the probe development efforts to identify inhibitors of human diacylglycerol lipase, beta (DAGLB) | summary | 3 | Summary (DAGLB inhibitors) |
| 624039 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based dose-response biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of antitarget ABHD6 in vitro, set 2 | confirmatory | ||
| 624077 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of mouse liver ABHD6 in vivo upon oral compound administration | other | ||
| 602415 | Assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): LC/MS-based biochemical inhibition of overexpressed DAGLb substrate turnover in vitro | other | ||
| 624041 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of mouse liver ABHD6 in vivo | other | ||
| 624468 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): LCMS-based biochemical dose response assay | confirmatory | ||
| 624472 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of DAGLb by enantiomers of KT116 | other | ||
| 602403 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of recombinant antitarget DAGLa in vitro | other |
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)
Affiliation: The Scripps Research Institute, TSRI
Assay Provider: Benjamin Cravatt, The Scripps Research Institute (TSRI)
Network: Molecular Library Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1 R01 DA025285
Grant Proposal PI: Benjamin Cravatt, The Scripps Research Institute (TSRI)
External Assay ID: DAGLB_INH_FLUO_1X%INH_SH_MBM_SET3
Name: Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of serine hydrolases in mouse brain membrane in vitro set 3.
Description:
Endocannabinoids (ECs) represent a unique group of lipids that function as chemical messengers in the nervous system. To date, the two principle ECs identified in mammals are N-arachidonoyl-ethanolamine (anandamide) and 2-arachidonoyl-glycerol (2-AG). They have been implicated in various physiological and pathological functions including appetite, pain, sensation, memory, and addiction (1). Unlike traditional neurotransmitters, which are stored in vesicles, ECs are synthesized and released on demand, and then rapidly degraded to terminate signaling. Thus, the metabolic pathways that govern EC turnover are critical in determining the magnitude and duration of neuronal signaling events (2). Endocannabinoid biosynthesis, in contrast to degradation, is poorly understood. Recently, two serine hydrolases, DAGL-a and -B, were cloned and found to selectively cleave sn-1 acyl chains from diacylglycerols (DAG) to generate 2-AG in vitro (3). Their function in the nervous system was validated in vivo by the generation of DAGL-a and -B knock-out mice (4, 5). However, it is still unclear to what extent DAGL-a/B catalytic activity contributes to 2-AG-mediated signaling. The development of potent and selective inhibitors would offer a means to perturb DAGL-a/B activity in a selective, reversible, and temporally-controlled manner. Given the non-selective nature of current DAGL-a/B inhibitors (6), specific chemical probes would serve as invaluable tools to delineate DAGL-a/B function in 2-AG signaling networks of the brain.
References:
1. Di Marzo, V. (2008) Targeting the endocannabinoid system: to enhance or reduce?, Nat Rev Drug Discov 7, 438-455.
2. Ahn, K., McKinney, M. K., and Cravatt, B. F. (2008) Enzymatic pathways that regulate endocannabinoid signaling in the nervous system, Chem Rev 108, 1687-1707.
3. Bisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M. G., Ligresti, A., Matias, I., Schiano-Moriello, A., Paul, P., Williams, E. J., Gangadharan, U., Hobbs, C., Di Marzo, V., and Doherty, P. (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain, J Cell Biol 163, 463-468.
4. Gao, Y., Vasilyev, D. V., Goncalves, M. B., Howell, F. V., Hobbs, C., Reisenberg, M., Shen, R., Zhang, M. Y., Strassle, B. W., Lu, P., Mark, L., Piesla, M. J., Deng, K., Kouranova, E. V., Ring, R. H., Whiteside, G. T., Bates, B., Walsh, F. S., Williams, G., Pangalos, M. N., Samad, T. A., and Doherty, P. (2010) Loss of Retrograde Endocannabinoid Signaling and Reduced Adult Neurogenesis in Diacylglycerol Lipase Knock-out Mice, J Neurosci 30, 2017-2024.
5. Tanimura, A., Yamazaki, M., Hashimotodani, Y., Uchigashima, M., Kawata, S., Abe, M., Kita, Y., Hashimoto, K., Shimizu, T., Watanabe, M., Sakimura, K., and Kano, M. (2010) The Endocannabinoid 2-Arachidonoylglycerol Produced by Diacylglycerol Lipase +/- Mediates Retrograde Suppression of Synaptic Transmission, Neuron 65, 320-327.
6. Hoover, H. S., Blankman, J. L., Niessen, S., and Cravatt, B. F. (2008) Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling, Bioorganic & Medicinal Chemistry Letters 18, 5838-5841.
Keywords:
late stage, late stage AID, assay provider, powders, counterscreen, diacylglycerol lipase, diacylglycerol lipase-beta, DAGL, DAGL-beta, DAGLB, hydrolase, serine hydrolase, appetite, pain, sensation, memory, addiction, activity-based protein profiling, ABPP, gel-based, activity-based probe, fluorophosphonate-rhodamine, FP-Rh, inhibitor, inhibition, serine hydrolases, mouse brain membrane, abhydrolase domain containing 6, ABHD6, acylpeptide hydrolase, APEH, fatty acid amide hydrolase, FAAH, lysophospholipase 1, LYPLA1, lysophospholipase 2, LYPLA2, Scripps, Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN
Affiliation: The Scripps Research Institute, TSRI
Assay Provider: Benjamin Cravatt, The Scripps Research Institute (TSRI)
Network: Molecular Library Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1 R01 DA025285
Grant Proposal PI: Benjamin Cravatt, The Scripps Research Institute (TSRI)
External Assay ID: DAGLB_INH_FLUO_1X%INH_SH_MBM_SET3
Name: Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of serine hydrolases in mouse brain membrane in vitro set 3.
Description:
Endocannabinoids (ECs) represent a unique group of lipids that function as chemical messengers in the nervous system. To date, the two principle ECs identified in mammals are N-arachidonoyl-ethanolamine (anandamide) and 2-arachidonoyl-glycerol (2-AG). They have been implicated in various physiological and pathological functions including appetite, pain, sensation, memory, and addiction (1). Unlike traditional neurotransmitters, which are stored in vesicles, ECs are synthesized and released on demand, and then rapidly degraded to terminate signaling. Thus, the metabolic pathways that govern EC turnover are critical in determining the magnitude and duration of neuronal signaling events (2). Endocannabinoid biosynthesis, in contrast to degradation, is poorly understood. Recently, two serine hydrolases, DAGL-a and -B, were cloned and found to selectively cleave sn-1 acyl chains from diacylglycerols (DAG) to generate 2-AG in vitro (3). Their function in the nervous system was validated in vivo by the generation of DAGL-a and -B knock-out mice (4, 5). However, it is still unclear to what extent DAGL-a/B catalytic activity contributes to 2-AG-mediated signaling. The development of potent and selective inhibitors would offer a means to perturb DAGL-a/B activity in a selective, reversible, and temporally-controlled manner. Given the non-selective nature of current DAGL-a/B inhibitors (6), specific chemical probes would serve as invaluable tools to delineate DAGL-a/B function in 2-AG signaling networks of the brain.
References:
1. Di Marzo, V. (2008) Targeting the endocannabinoid system: to enhance or reduce?, Nat Rev Drug Discov 7, 438-455.
2. Ahn, K., McKinney, M. K., and Cravatt, B. F. (2008) Enzymatic pathways that regulate endocannabinoid signaling in the nervous system, Chem Rev 108, 1687-1707.
3. Bisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M. G., Ligresti, A., Matias, I., Schiano-Moriello, A., Paul, P., Williams, E. J., Gangadharan, U., Hobbs, C., Di Marzo, V., and Doherty, P. (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain, J Cell Biol 163, 463-468.
4. Gao, Y., Vasilyev, D. V., Goncalves, M. B., Howell, F. V., Hobbs, C., Reisenberg, M., Shen, R., Zhang, M. Y., Strassle, B. W., Lu, P., Mark, L., Piesla, M. J., Deng, K., Kouranova, E. V., Ring, R. H., Whiteside, G. T., Bates, B., Walsh, F. S., Williams, G., Pangalos, M. N., Samad, T. A., and Doherty, P. (2010) Loss of Retrograde Endocannabinoid Signaling and Reduced Adult Neurogenesis in Diacylglycerol Lipase Knock-out Mice, J Neurosci 30, 2017-2024.
5. Tanimura, A., Yamazaki, M., Hashimotodani, Y., Uchigashima, M., Kawata, S., Abe, M., Kita, Y., Hashimoto, K., Shimizu, T., Watanabe, M., Sakimura, K., and Kano, M. (2010) The Endocannabinoid 2-Arachidonoylglycerol Produced by Diacylglycerol Lipase +/- Mediates Retrograde Suppression of Synaptic Transmission, Neuron 65, 320-327.
6. Hoover, H. S., Blankman, J. L., Niessen, S., and Cravatt, B. F. (2008) Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling, Bioorganic & Medicinal Chemistry Letters 18, 5838-5841.
Keywords:
late stage, late stage AID, assay provider, powders, counterscreen, diacylglycerol lipase, diacylglycerol lipase-beta, DAGL, DAGL-beta, DAGLB, hydrolase, serine hydrolase, appetite, pain, sensation, memory, addiction, activity-based protein profiling, ABPP, gel-based, activity-based probe, fluorophosphonate-rhodamine, FP-Rh, inhibitor, inhibition, serine hydrolases, mouse brain membrane, abhydrolase domain containing 6, ABHD6, acylpeptide hydrolase, APEH, fatty acid amide hydrolase, FAAH, lysophospholipase 1, LYPLA1, lysophospholipase 2, LYPLA2, Scripps, Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN
Panel Information
Targets
§ Panel component ID.
| Data Table(Active) Data Table(All) | Show more |
| PID§ | Name | Substance | Panel Targets | Description | Additional Information | ||
|---|---|---|---|---|---|---|---|
| Active | Inactive | ||||||
| 1 | ABHD6 | 12 | monoacylglycerol lipase ABHD6 [Mus musculus] [gi:31560264] | Taxonomy id: 10090 Gene id: 66082 | |||
| 2 | APEH | 1 | 11 | Acylpeptide hydrolase [Mus musculus] [gi:19343726] | Taxonomy id: 10090 Gene id: 235606 | ||
| 3 | FAAH | 7 | 5 | fatty acid amide hydrolase [Mus musculus] [gi:123253900] | Taxonomy id: 10090 Gene id: 14073 | ||
| 4 | LYPLA1 | 7 | 5 | acyl-protein thioesterase 2 [Mus musculus] [gi:7242156] | Taxonomy id: 10090 Gene id: 26394 | ||
| 5 | LYPLA2 | 7 | 5 | acyl-protein thioesterase 1 [Mus musculus] [gi:6678760] | Taxonomy id: 10090 Gene id: 18777 | ||
§ Panel component ID.
Protocol
Assay Overview:
The purpose of this assay is to assess test compound inhibition of serine hydroases (SHs) in a complex proteome using a gel-based competitive activity-based proteomic profiling (ABPP) assay. In this assay, a complex proteome is incubated with test compound followed by reaction with a fluorescently-labeled serine hydrolase-specific activity-based probe, fluorophosphonate-rhodamine (FP-Rh). The reaction products are separated by SDS-PAGE and visualized in-gel using a flatbed fluorescence scanner. The percentage activity remaining is determined by measuring the integrated optical density (IOD) of the bands. As designed, test compounds that act as SH inhibitors will prevent enzyme-probe interactions, thereby decreasing the proportion of bound fluorescent probe, giving lower fluorescence intensity in the band in the gel.
Protocol Summary:
Mouse brain membrane proteome (25 uL of 1 mg/mL in Dulbecco's PBS [DPBS]) was treated with test compound (0.5 uL of a 50x stock in DMSO; 10 uM or 1 uM final concentration) or DMSO (0.5 uL) for 30 minutes at 37 C. The activity-based probe FP-Rh (0.5 uL of a 50x stock in DMSO; 1 uM final concentration) was added, and the reaction was incubated for 30 minutes at 37 C quenched with an equal volume of 2x SDS-PAGE loading buffer (reducing), separated by SDS-PAGE, and visualized by in-gel fluorescent scanning. The percentage activity remaining for each SH was determined by measuring the integrated optical density of the individual protein bands relative to the DMSO-only (no compound) control. SHs with at least 50% inhibition by one or more compounds (abhydrolase domain containing 6 [ABHD6], acylpeptide hydrolase [APEH], fatty acid amide hydrolase [FAAH], lysophospholipase 1 [LYPLA1], and lysophospholipase 2 [LYPLA2]) are reported.
The percent inhibition for each compound was calculated as follows:
%_Inhibition = ( 1 -( IOD_Test_Compound - Median_IOD_Low_Control ) / ( Median_IOD_High_Contro - MedianIOD_Low_Control ) ) * 100
Where:
Test_Compound is defined as SH treated with test compound.
High_Control is defined as SH treated with DMSO only (no compound).
Low_Control is defined as background in a blank region of the gel.
PubChem Activity Outcome and Score:
The following applies to each panel in this assay:
Compounds with greater than or equal to 50% inhibition for a given SH at 10 uM test compound concentration were considered active. Compounds with less than 50% inhibition for a given SH at 10 uM test compound concentration were considered inactive.
The reported PubChem Activity Score has been normalized to 100% observed inhibition. Negative % inhibition values are reported as activity score zero.
ABDH6 Score: The PubChem Activity Score range for active compounds is 100-98. There are no inactive compounds.
APEH Score: The PubChem Activity Score range for active compounds is 100-100, and for inactive compounds 45-0.
FAAH Score: The PubChem Activity Score range for active compounds is 100-86, and for inactive compounds 35-0.
LYPLA2 Score: The PubChem Activity Score range for active compounds is 100-90, and for inactive compounds 25-0.
LYPLA1 Score: The PubChem Activity Score range for active compounds is 100-90, and for inactive compounds 25-0.
Overall Outcome and Score:
Compounds active against at least one SH at 10 uM test compound concentration were considered active. Compounds inactive against all SHs at 10 uM test compound concentration were considered inactive.
The PubChem Activity Score is assigned a value of 100 for active compounds, and 0 for inactive compounds.
The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
List of Reagents:
Mouse brain membrane proteome (provided by Assay Provider)
FP-Rh (provided by Assay Provider)
DPBS (Cellgro 20-031-CV)
The purpose of this assay is to assess test compound inhibition of serine hydroases (SHs) in a complex proteome using a gel-based competitive activity-based proteomic profiling (ABPP) assay. In this assay, a complex proteome is incubated with test compound followed by reaction with a fluorescently-labeled serine hydrolase-specific activity-based probe, fluorophosphonate-rhodamine (FP-Rh). The reaction products are separated by SDS-PAGE and visualized in-gel using a flatbed fluorescence scanner. The percentage activity remaining is determined by measuring the integrated optical density (IOD) of the bands. As designed, test compounds that act as SH inhibitors will prevent enzyme-probe interactions, thereby decreasing the proportion of bound fluorescent probe, giving lower fluorescence intensity in the band in the gel.
Protocol Summary:
Mouse brain membrane proteome (25 uL of 1 mg/mL in Dulbecco's PBS [DPBS]) was treated with test compound (0.5 uL of a 50x stock in DMSO; 10 uM or 1 uM final concentration) or DMSO (0.5 uL) for 30 minutes at 37 C. The activity-based probe FP-Rh (0.5 uL of a 50x stock in DMSO; 1 uM final concentration) was added, and the reaction was incubated for 30 minutes at 37 C quenched with an equal volume of 2x SDS-PAGE loading buffer (reducing), separated by SDS-PAGE, and visualized by in-gel fluorescent scanning. The percentage activity remaining for each SH was determined by measuring the integrated optical density of the individual protein bands relative to the DMSO-only (no compound) control. SHs with at least 50% inhibition by one or more compounds (abhydrolase domain containing 6 [ABHD6], acylpeptide hydrolase [APEH], fatty acid amide hydrolase [FAAH], lysophospholipase 1 [LYPLA1], and lysophospholipase 2 [LYPLA2]) are reported.
The percent inhibition for each compound was calculated as follows:
%_Inhibition = ( 1 -( IOD_Test_Compound - Median_IOD_Low_Control ) / ( Median_IOD_High_Contro - MedianIOD_Low_Control ) ) * 100
Where:
Test_Compound is defined as SH treated with test compound.
High_Control is defined as SH treated with DMSO only (no compound).
Low_Control is defined as background in a blank region of the gel.
PubChem Activity Outcome and Score:
The following applies to each panel in this assay:
Compounds with greater than or equal to 50% inhibition for a given SH at 10 uM test compound concentration were considered active. Compounds with less than 50% inhibition for a given SH at 10 uM test compound concentration were considered inactive.
The reported PubChem Activity Score has been normalized to 100% observed inhibition. Negative % inhibition values are reported as activity score zero.
ABDH6 Score: The PubChem Activity Score range for active compounds is 100-98. There are no inactive compounds.
APEH Score: The PubChem Activity Score range for active compounds is 100-100, and for inactive compounds 45-0.
FAAH Score: The PubChem Activity Score range for active compounds is 100-86, and for inactive compounds 35-0.
LYPLA2 Score: The PubChem Activity Score range for active compounds is 100-90, and for inactive compounds 25-0.
LYPLA1 Score: The PubChem Activity Score range for active compounds is 100-90, and for inactive compounds 25-0.
Overall Outcome and Score:
Compounds active against at least one SH at 10 uM test compound concentration were considered active. Compounds inactive against all SHs at 10 uM test compound concentration were considered inactive.
The PubChem Activity Score is assigned a value of 100 for active compounds, and 0 for inactive compounds.
The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
List of Reagents:
Mouse brain membrane proteome (provided by Assay Provider)
FP-Rh (provided by Assay Provider)
DPBS (Cellgro 20-031-CV)
Comment
This assay was performed by the assay provider with powder samples of synthetic compounds.
Categorized Comment
BAO: version: 1.4b1090
BAO: bioassay specification: assay stage: secondary: selectivity
BAO: bioassay specification: assay biosafety level: bsl1
BAO: assay format: biochemical format: protein format: single protein format
BAO: bioassay specification: assay measurement type: endpoint assay
BAO: bioassay specification: assay readout content: assay readout method: regular screening
BAO: bioassay specification: assay readout content: content readout type: single readout
BAO: meta target: molecular target: protein target: enzyme: generic hydrolase
BAO: meta target: biological process target: regulation of molecular function
BAO: meta target detail: binding reporter specification: interaction: protein-small molecule
BAO: detection technology: fluorescence: fluorescence intensity
BAO: bioassay specification: assay stage: secondary: selectivity
BAO: bioassay specification: assay biosafety level: bsl1
BAO: assay format: biochemical format: protein format: single protein format
BAO: bioassay specification: assay measurement type: endpoint assay
BAO: bioassay specification: assay readout content: assay readout method: regular screening
BAO: bioassay specification: assay readout content: content readout type: single readout
BAO: meta target: molecular target: protein target: enzyme: generic hydrolase
BAO: meta target: biological process target: regulation of molecular function
BAO: meta target detail: binding reporter specification: interaction: protein-small molecule
BAO: detection technology: fluorescence: fluorescence intensity
Result Definitions
| Show more |
| TID | Name | Description | PID§ | Panel Targets | Histogram | Type | Unit | |
|---|---|---|---|---|---|---|---|---|
| Outcome | The BioAssay activity outcome | Outcome | ||||||
| Score | The BioAssay activity ranking score |  | Integer | |||||
| 1 | Outcome [ABHD6] | One of Active, Inactive, or Not Tested | 1 | monoacylglycerol lipase ABHD6 [Mus musculus] | | Outcome | ||
| 2 | Score [ABHD6] | BioAssay Score. | 1 | | Integer | |||
| 3 | Inhibition at 10 uM [ABHD6] (10μM**) | Inhibition of endogenous mouse ABHD6 upon 10 uM compound treatment as assessed by gel-based competitive ABPP. | 1 | | Integer | % | ||
| 4 | Inhibition at 1 uM [ABHD6] (1μM**) | Inhibition of endogenous mouse ABHD6 upon 1 uM compound treatment as assessed by gel-based competitive ABPP. | 1 | | Integer | % | ||
| 5 | Outcome [APEH] | One of Active, Inactive, or Not Tested | 2 | Acylpeptide hydrolase [Mus musculus] | | Outcome | ||
| 6 | Score [APEH] | BioAssay Score. | 2 | | Integer | |||
| 7 | Inhibition at 10 uM [APEH] (10μM**) | Inhibition of endogenous mouse APEH upon 10 uM compound treatment as assessed by gel-based competitive ABPP. | 2 | | Integer | % | ||
| 8 | Inhibition at 1 uM [APEH] (1μM**) | Inhibition of endogenous mouse APEH upon 1 uM compound treatment as assessed by gel-based competitive ABPP. | 2 | | Integer | % | ||
| 9 | Outcome [FAAH] | One of Active, Inactive, or Not Tested | 3 | fatty acid amide hydrolase [Mus musculus] | | Outcome | ||
| 10 | Score [FAAH] | BioAssay Score. | 3 | | Integer | |||
| 11 | Inhibition at 10 uM [FAAH] (10μM**) | Inhibition of endogenous mouse FAAH upon 10 uM compound treatment as assessed by gel-based competitive ABPP. | 3 | | Integer | % | ||
| 12 | Inhibition at 1 uM [FAAH] (1μM**) | Inhibition of endogenous mouse FAAH upon 1 uM compound treatment as assessed by gel-based competitive ABPP. | 3 | | Integer | % | ||
| 13 | Outcome [LYPLA2] | One of Active, Inactive, or Not Tested | 4 | acyl-protein thioesterase 2 [Mus musculus] | | Outcome | ||
| 14 | Score [LYPLA2] | BioAssay Score. | 4 | | Integer | |||
| 15 | Inhibition at 10 uM [LYPLA2] (10μM**) | Inhibition of endogenous mouse LYPLA2 upon 10 uM compound treatment as assessed by gel-based competitive ABPP. | 4 | | Integer | % | ||
| 16 | Inhibition at 1 uM [LYPLA2] (1μM**) | Inhibition of endogenous mouse LYPLA2 upon 1 uM compound treatment as assessed by gel-based competitive ABPP. | 4 | | Integer | % | ||
| 17 | Outcome [LYPLA1] | One of Active, Inactive, or Not Tested | 5 | acyl-protein thioesterase 1 [Mus musculus] | | Outcome | ||
| 18 | Score [LYPLA1] | BioAssay Score. | 5 | | Integer | |||
| 19 | Inhibition at 10 uM [LYPLA1] (10μM**) | Inhibition of endogenous mouse LYPLA1 upon 10 uM compound treatment as assessed by gel-based competitive ABPP. | 5 | | Integer | % | ||
| 20 | Inhibition at 1 uM [LYPLA1] (1μM**) | Inhibition of endogenous mouse LYPLA1 upon 1 uM compound treatment as assessed by gel-based competitive ABPP. | 5 | | Integer | % |
** Test Concentration. § Panel component ID.
Additional Information
Grant Number: 1 R01 DA025285
Classification
PageFrom: